iBio, Inc. (IBIO)
$0.78-13.33%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $12M
- Beta
- 1.26
- P/E (TTM)
- -2.40
- Short % float
- 28.13%
- Days to cover
- 6.2
- SI change
- -14.9%
- 1W
- -25.71%
- 1M
- -35.00%
- vs SPY 1W
- -25.58%
- vs SPY 1M
- -37.51%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 5
- GROWTH
- 23
- GARP
- 7
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-28.7%
REV YoY-
ROE-12.4%
EPS YoY-
ROA-33.3%
GROSS100
OP-35141
NET-33044
[VALUATION]
P/E TTM-2.40
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.95
P/FCF-
EV/EBITDA0.12
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E2.56
ALTMAN Z-
CURR RATIO7.85
ND/EBITDA-
BETA1.26
NET INCOME (TTM) < 0
Company news
FAQ
- What is LOPJLB’s current signal on IBIO?
- LOPJLB’s latest quantitative signal on iBio, Inc. (IBIO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IBIO in?
- iBio, Inc. (IBIO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does iBio, Inc. (IBIO) do?
- iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at…